BG
DNTH icon

Bollard Group’s Dianthus Therapeutics DNTH Stock Holding History

Bollard Group’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,750
Closed -$220K – 434
2020
Q4 		$220K Hold
1,750
– – 0.01% 196
2020
Q3 		$190K Hold
1,750
– – 0.01% 196
2020
Q2 		$210K Hold
1,750
– – 0.01% 183
2020
Q1 		$176K Hold
1,750
– – 0.01% 144
2019
Q4 		$424K Hold
1,750
– – 0.01% 138
2019
Q3 		$287K Sell
1,750
-125
-7% -$23.7K 0.01% 147
2019
Q2 		$442K Hold
1,875
– – 0.02% 151
2019
Q1 		$494K Hold
1,875
– – 0.02% 147
2018
Q4 		$171K Hold
1,875
– – 0.01% 172
2018
Q3 		$360K Buy
+1,875
New +$395K 0.01% 155

Other funds holding DNTH

TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Bollard Group's DNTH Position: Q1 2021 in Review

Bollard Group sold out of Dianthus Therapeutics (DNTH) in Q1 2021, closing a stake of 1,750 shares — an estimated $220K sold.

Bollard Group first reported a position in DNTH in Q3 2018 and held it in 10 quarters. The position peaked at $494K in Q1 2019. 90 funds tracked by Wall St. Rank hold DNTH as of Q1 2021.

  • Bollard Group reported no remaining Dianthus Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Bollard Group sold 1,750 Dianthus Therapeutics shares in Q1 2021, an estimated $220K.
  • Bollard Group first reported a position in Dianthus Therapeutics in Q3 2018 and held it in 10 quarters.
  • Bollard Group's Dianthus Therapeutics position peaked at $494K in Q1 2019.
  • 90 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2021.

Based on Bollard Group's 13F filing for Q1 2021, filed 11 May 2021.